Yahoo Finance Insider Buying Alert: COO Pat Beyer Acquires Shares of Conmed Corp (CNMD)
On April 30, 2024, Pat Beyer, Chief Operating Officer of Conmed Corp (NYSE:CNMD), purchased 3,000 shares of the company, as reported in a recent SEC Filing. This transaction increased the total number of shares owned by the insider to 3,000, as the insider had not sold any shares in the past year.
Conmed Corp (NYSE:CNMD) is a medical technology company specializing in surgical instruments and devices for minimally invasive procedures and monitoring. The company's products are used in a variety of specialties, including orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology.
The purchase occurred at a price of $68.3 per share, valuing the transaction at approximately $204,900. Following this acquisition, the market cap of Conmed Corp stands at $2.16 billion.
Analyzing the valuation metrics, Conmed Corp's price-earnings ratio is 26.89, which is below both the industry median of 29.16 and the companys historical median. This suggests a potentially lower valuation relative to its peers and its own past.
The GF Value of Conmed Corp is calculated at $127.58, indicating that with the current price of $68.3, the stock is significantly undervalued, with a price-to-GF-Value ratio of 0.54.
The insider transaction history for Conmed Corp shows a trend of more insider sales than buys over the past year, with 10 insider sells and only 1 insider buy, which includes the recent purchase by the insider.
The GF Value, an intrinsic value estimate from GuruFocus, considers historical trading multiples, a GuruFocus adjustment factor based on past returns and growth, and future business performance estimates from analysts.
This insider buying activity could be a signal to investors, especially considering the stocks current valuation and GF Value status.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
